Pure Biologics Revenue
Biotechnology Research • 
Wrocław, Lower Silesian Voivodeship, Poland • 21-50 Employees
Pure Biologics revenue & valuation
| Annual revenue | $20,000,000 |
| Revenue per employee | $953,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $64,000,000 |
| Total funding | No funding |
Key Contacts at Pure Biologics
Niina Veitonmä
Senior Director Non-Clinical Drug Development, Supervisor Immuno-Oncology Portfolio
Filip Jelen
Founder & Ceo
Ewelina Świderek
Head Of Project Management | Director Of Project Portfolio
Monika Jory
Non-Executive Director
Company overview
| Headquarters | Duńska, 11, Wroclaw, Lower Silesia 54-427, PL |
| Phone number | +480000712811 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, CRO, R&D, Antibodies, Bioassays, Proteins, Recombinant Proteins, Immunoassays, Aptamers, Protein Expression, Biophysical Analysis, Early-Stage Drug Development |
| Founded | 2010 |
| Employees | 21-50 |
| Socials |
Pure Biologics Email Formats
Pure Biologics uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@purebiologics.com), used 53.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@purebiologics.com | 53.3% |
{first initial}.{last name} | j.doe@purebiologics.com | 26.7% |
{first initial} | j@purebiologics.com | 13.3% |
{last name}.{last name} | doe.doe@purebiologics.com | 6.7% |
About Pure Biologics
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers. Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterisation of antibodies and aptamers, as well as protein production, purification and analysis. The company is implementing a project titled "Development of a bispecific antibody fragment for the simultaneous targeting of cancer and recruitment of immune system cells [PHASE II]", co-financed by the European Funds for the Modern Economy 2021-2027 (FENG) under action 01.01 SMART Pathways – R&D module of the FENG Program. Agreement No. FENG.01.01-IP.01-1008/23-00 dated 26.09.2024. Project cost: 7,831,250 PLN Funding amount: 4,415,625.00 PLN Project Subject: The subject of the project is R&D work in the area of innovative medical solutions and the implementation of innovations at a global level. Project Objective: A phase 0 clinical trial in patients with solid tumors, which will confirm the mechanism of action and, consequently, the anti-cancer activity of PBA-0405 in the complex microenvironment of human tumors. Project implementation period: 01.01.2024 – 30.06.2025 Contact: info@purebiologics.com | inwestor@purebiologics.com | recruitment@purebiologics.com
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Pure Biologics has 8 employees across 4 departments.
Departments
Number of employees
Funding Data
Pure Biologics has never raised funding before.
Pure Biologics Tech Stack
Discover the technologies and tools that power Pure Biologics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Tag managers
Reverse proxies
Form builders
Programming languages
Miscellaneous
Analytics
Blogs
JavaScript libraries
Miscellaneous
JavaScript libraries
Analytics
Saudi Arabia
Saint Vincent and the Grenadines
Belgium
DenmarkFrequently asked questions
4.8
40,000 users
